You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

131 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade, 
Multiple Myeloma
Intent: Palliative
Dec 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Dec 2017
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
Dec 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Dec 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Dec 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Dec 2017
Guidelines and Advice
Drug
Other Name(s): Rituxan® SC
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
Jun 2025
Regimen
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma, based on criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Jun 2025

Pages